RxSight, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a RXST research report →
Range $5.5 – $7
Price Chart
About the company
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs).
- CEO
- Aziz Mottiwala
- IPO
- 2021
- Employees
- 461
- HQ
- Aliso Viejo, CA, US
Get TickerSpark's AI analysis on RXST
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $187.42M
- P/E
- -3.60
- PEG
- 0.10
- P/S
- 1.59
- P/B
- 0.75
- EV/EBITDA
- -2.76
- Div Yield
- 0.00%
- Gross Margin
- 76.13%
- Op Margin
- -50.44%
- Net Margin
- -43.80%
- ROE
- -20.11%
- ROIC
- -22.99%
Latest fiscal year · YoY change
- Revenue
- $134.48M-3.9%
- Gross Profit
- $103.01M+4.1%
- Op Income
- $-48,190,000
- Net Income
- $-38,943,000-41.8%
- EPS
- $-0.95-33.8%
- OCF Growth
- +8.5%
- FCF Growth
- +13.6%
- 52W High
- $13.22
- 52W Low
- $4.11
- 50D MA
- $4.90
- 200D MA
- $6.05
- Beta
- 1.19
- RSI (14)
- 41
- Avg Volume
- 826.96K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
RxSight said third-quarter results were pressured by competition, seasonality and restructuring disruption, but management is refocusing the business on U.S. LAL utilization, next-gen lens development and the Alcon partnership.· November 3, 2026
- Q3 revenue was $24.6 million, down 19% year over year, with LAL procedure revenue of $22.8 million and procedure volume of 23,128 units, down 11%.
- Gross margin fell to 73.6% from 79.9% a year ago, mainly due to higher inventory reserves; SG&A was $27.4 million and R&D was $9.2 million.
- Management said competitive pressure from recent launches and free-product trialing, plus internal disruption from restructuring and sales-force changes, weighed on the quarter.
- RxSight nearly doubled the U.S. sales force and is shifting resources toward deeper adoption in the installed base rather than prioritizing LDD placements.
- The company is not giving full-year 2026 guidance and expects to resume guidance for 2027 when it reports fourth-quarter results next year.
Third-quarter 2026 total revenue was $24.6 million, down 19% from $30.3 million in the prior-year period. LAL procedure volume revenue was $22.8 million, and LAL procedure volume was 23,128 units, down 11% from 26,045 units a year ago. Gross margin was 73.6% versus 79.9% last year. SG&A was $27.4 million, R&D was $9.2 million, net loss was $16.2 million or $0.39 per share, and adjusted net loss was $8.6 million or $0.21 per share. Cash, cash equivalents and short-term investments were $254.7 million, including $60 million from the Alcon collaboration upfront payment. Management is not providing formal full-year 2026 guidance and expects to resume financial guidance for 2027 with fourth-quarter results early next year; for Q4, management said LAL sales should be more in line with Q2, which would imply mid- to high single-digit sequential growth from Q3.
Aziz Mottiwala framed his first 90 days as a strategic reset, saying the company has clear priorities: strengthen the U.S. LAL business, advance the next-generation adjustable lens, and execute on Alcon. He emphasized that most commercial problems appear fixable through better field coverage, practice integration, and more disciplined execution rather than structural market issues. His tone was optimistic but candid: he repeatedly acknowledged near-term pain from restructuring and competition while arguing those changes are necessary to build a more scalable, durable business.
Mark Wilterding focused on the financial impact of the quarter and the restructuring. He reported revenue of $24.6 million, gross margin of 73.6%, SG&A of $27.4 million, R&D of $9.2 million, and cash of $254.7 million, including the $60 million Alcon upfront payment. He said the restructuring across manufacturing, corporate functions and international operations should generate meaningful expense savings in the base business, with benefits expected in 2027 and beyond, and that OpEx should be lower in 2027 than in 2026 even while continuing to fund U.S. commercial expansion, Alcon and next-gen development.
Analysts pressed management on whether the business worsened sequentially in Q3, and Aziz said the decline reflected seasonality, ongoing competitive pressure from recent launches and free-product trialing, and internal disruption from the restructuring and sales-force expansion. Asked about Q4, Mark said he expects LAL sales to look more like Q2 and called out continued competitive activity and restructuring-related disruption, but noted October trends were encouraging. Management also said the company is intentionally deemphasizing LDD placements, expecting only a handful going forward, while keeping focus on driving utilization in the installed base and using the sales force to improve frequency, workflow support and patient selection.
The bull case is that RxSight believes the demand problem is primarily commercial execution, not product weakness, and management sees pockets where higher rep frequency and better practice integration are already driving strong utilization. The company has a large installed base, a strong cash position, and a clearer strategic focus, while the Alcon partnership and next-gen lens could broaden the addressable market later.
The bear case is that Q3 showed a 19% revenue decline, an 11% drop in procedure volume and a gross margin reset, with management explicitly citing competitive pressure and internal disruption. Management is also signaling continued near-term volatility, no formal 2026 guidance, limited LDD sales going forward, and only an earliest possible 2028 approval timeframe for the next-gen lens.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 92.8%
- Shares Outstanding
- 41.93M
- Float Shares
- 38.89M
of shares held by institutions
154 13F filers
Buy/sell ratio 0.92. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 6.34M | ▲ 552.23K |
| Millennium Management LLC | 3.03M | ▲ 970.83K |
| Vanguard Group Inc | 2.23M | ▲ 82.48K |
| No Street Gp LP | 2.06M | ▲ 55.00K |
| Nomura Holdings Inc | 2.00M | 0 |
| D. E. Shaw & Co., Inc. | 1.99M | ▲ 25.48K |
| Vanguard Capital Management LLC | 1.68M | 0 |
| Aqr Capital Management LLC | 1.53M | ▲ 897.70K |
| Acadian Asset Management LLC | 1.45M | ▼ 52.32K |
| Federated Hermes, Inc. | 1.22M | ▲ 14.45K |
| Two Sigma Investments, LP | 1.15M | ▼ 153.21K |
| Jacobs Levy Equity Management, Inc | 998.57K | ▼ 67.75K |
Held by 138 ETFs
Biggest fund positions in RXST by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Sep 15, 26 | Weinberg Eric | other | 35,168 |
| Sep 15, 26 | Weinberg Eric | other | 35,168 |
| Sep 5, 26 | Wilterding Mark | other | 258,770 |
| Sep 5, 26 | Wilterding Mark | sell | 258,770 |
| Sep 5, 26 | Weinberg Eric | other | 93,984 |
| Sep 5, 26 | Weinberg Eric | other | 82,608 |
| Sep 5, 26 | Weinberg Eric | other | 65,742 |
| Sep 5, 26 | Weinberg Eric | other | 59,483 |
| Sep 5, 26 | Weinberg Eric | other | 32,258 |
| Sep 5, 26 | Weinberg Eric | sell | 92,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our RXST coverage
Recent articles, reports, and earnings notes.
No research on RXST yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate RXST report →RxSight, Inc. to Present at the Piper Sandler Healthcare Conference
globenewswire.com · Nov 19
RxSight, Inc. (RXST) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 3
What RxSight (RXST) Said on Its Q3 Earnings Call
marketbeat.com · Nov 3
RxSight, Inc. (RXST) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 3
RxSight, Inc. Reports Third Quarter 2026 Results
globenewswire.com · Nov 3
RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules
globenewswire.com · Oct 23
RxSight, Inc. to Report Third Quarter 2026 Financial Results on November 3
globenewswire.com · Oct 20
RxSight Appoints Eye Care Industry Leaders to Drive Commercial Transformation
globenewswire.com · Oct 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.